EpiTherapeutics and Abbott Enter Into Oncology Collaboration on Epigenetic Targets
The collaboration agreement runs for three years. Research activities will be conducted at both EpiTherapeutics and Abbott.
Dr. Martin Bonde, CEO of EpiTherapeutics, commented: "We are very pleased with our drug discovery collaboration with Abbott, who brings tremendous expertise in the oncology field. Abbott's choice of EpiTherapeutics as a collaboration partner is recognition of our competencies within epigenetic biology and early drug discovery. We look forward to a fruitful collaboration with the aim of developing new anti-cancer drugs within the promising new area of epigenetics."
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.